Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.
Identifieur interne : 000548 ( Main/Exploration ); précédent : 000547; suivant : 000549Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.
Auteurs : Saiju Jacob [Royaume-Uni] ; Srikanth Muppidi [États-Unis] ; Amanda Guidon [États-Unis] ; Jeffrey Guptill [États-Unis] ; Michael Hehir [États-Unis] ; James F. Howard [États-Unis] ; Isabel Illa [Espagne] ; Renato Mantegazza [Italie] ; Hiroyuki Murai [Japon] ; Kimiaki Utsugisawa [Japon] ; John Vissing [Danemark] ; Heinz Wiendl [Allemagne] ; Richard J. Nowak [États-Unis]Source :
- Journal of the neurological sciences [ 1878-5883 ] ; 2020.
Descripteurs français
- KwdFr :
- Betacoronavirus (MeSH), Essais cliniques comme sujet (MeSH), Facteurs immunologiques (usage thérapeutique), Humains (MeSH), Immunoglobulines par voie veineuse (usage thérapeutique), Immunosuppresseurs (usage thérapeutique), Immunothérapie (MeSH), Infections à coronavirus (complications), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (épidémiologie), Myasthénie (complications), Myasthénie (thérapie), Myasthénie (traitement médicamenteux), Pandémies (MeSH), Pneumopathie virale (complications), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (épidémiologie), Prise en charge de la maladie (MeSH), Prédisposition aux maladies (MeSH), Syndrome myasthénique de Lambert-Eaton (complications), Syndrome myasthénique de Lambert-Eaton (thérapie), Syndrome myasthénique de Lambert-Eaton (traitement médicamenteux), Vaccins (MeSH), Échange plasmatique (MeSH).
- MESH :
- thérapie : Myasthénie, Syndrome myasthénique de Lambert-Eaton.
- traitement médicamenteux : Infections à coronavirus, Myasthénie, Pneumopathie virale, Syndrome myasthénique de Lambert-Eaton.
- usage thérapeutique : Facteurs immunologiques, Immunoglobulines par voie veineuse, Immunosuppresseurs, Infections à coronavirus, Myasthénie, Pneumopathie virale, Syndrome myasthénique de Lambert-Eaton.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Betacoronavirus, Essais cliniques comme sujet, Humains, Immunothérapie, Pandémies, Prise en charge de la maladie, Prédisposition aux maladies, Vaccins, Échange plasmatique.
English descriptors
- KwdEn :
- Betacoronavirus (MeSH), COVID-19 (MeSH), Clinical Trials as Topic (MeSH), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Disease Management (MeSH), Disease Susceptibility (MeSH), Humans (MeSH), Immunoglobulins, Intravenous (therapeutic use), Immunologic Factors (therapeutic use), Immunosuppressive Agents (therapeutic use), Immunotherapy (MeSH), Lambert-Eaton Myasthenic Syndrome (complications), Lambert-Eaton Myasthenic Syndrome (drug therapy), Lambert-Eaton Myasthenic Syndrome (therapy), Myasthenia Gravis (complications), Myasthenia Gravis (drug therapy), Myasthenia Gravis (therapy), Pandemics (MeSH), Plasma Exchange (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), SARS-CoV-2 (MeSH), Vaccines (MeSH).
- MESH :
- chemical , therapeutic use : Immunoglobulins, Intravenous, Immunologic Factors, Immunosuppressive Agents.
- complications : Coronavirus Infections, Lambert-Eaton Myasthenic Syndrome, Myasthenia Gravis, Pneumonia, Viral.
- drug therapy : Coronavirus Infections, Lambert-Eaton Myasthenic Syndrome, Myasthenia Gravis, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- therapy : Lambert-Eaton Myasthenic Syndrome, Myasthenia Gravis.
- Betacoronavirus, COVID-19, Clinical Trials as Topic, Disease Management, Disease Susceptibility, Humans, Immunotherapy, Pandemics, Plasma Exchange, SARS-CoV-2, Vaccines.
DOI: 10.1016/j.jns.2020.116803
PubMed: 32247193
PubMed Central: PMC7105910
Affiliations:
- Allemagne, Danemark, Espagne, Italie, Japon, Royaume-Uni, États-Unis
- Californie, Caroline du Nord, Catalogne, Connecticut, District de Münster, Massachusetts, Rhénanie-du-Nord-Westphalie, Vermont
- Chapel Hill (Caroline du Nord), Münster
- Université de Caroline du Nord à Chapel Hill
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.</title><author><name sortKey="Jacob, Saiju" sort="Jacob, Saiju" uniqKey="Jacob S" first="Saiju" last="Jacob">Saiju Jacob</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Institute of Immunology and Immunotherapy, University Hospitals, Birmingham B15 2TH, United Kingdom. Electronic address: saiju.jacob@uhb.nhs.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurology, Institute of Immunology and Immunotherapy, University Hospitals, Birmingham B15 2TH</wicri:regionArea><wicri:noRegion>Birmingham B15 2TH</wicri:noRegion></affiliation></author><author><name sortKey="Muppidi, Srikanth" sort="Muppidi, Srikanth" uniqKey="Muppidi S" first="Srikanth" last="Muppidi">Srikanth Muppidi</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Stanford Neuroscience Health Center, Palo Alto, CA 94304, USA. Electronic address: muppidis@stanford.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Stanford Neuroscience Health Center, Palo Alto, CA 94304</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Guidon, Amanda" sort="Guidon, Amanda" uniqKey="Guidon A" first="Amanda" last="Guidon">Amanda Guidon</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Massachusetts General Hospital, Boston, MA 02114</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Guptill, Jeffrey" sort="Guptill, Jeffrey" uniqKey="Guptill J" first="Jeffrey" last="Guptill">Jeffrey Guptill</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Duke University Medical Center, Durham, NC 27710</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Hehir, Michael" sort="Hehir, Michael" uniqKey="Hehir M" first="Michael" last="Hehir">Michael Hehir</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, University of Vermont Medical Center, Burlington, VT 05401, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Vermont Medical Center, Burlington, VT 05401</wicri:regionArea><placeName><region type="state">Vermont</region></placeName></affiliation></author><author><name sortKey="Howard, James F" sort="Howard, James F" uniqKey="Howard J" first="James F" last="Howard">James F. Howard</name><affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7025, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7025</wicri:regionArea><placeName><region type="state">Caroline du Nord</region><settlement type="city">Chapel Hill (Caroline du Nord)</settlement></placeName><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName></affiliation></author><author><name sortKey="Illa, Isabel" sort="Illa, Isabel" uniqKey="Illa I" first="Isabel" last="Illa">Isabel Illa</name><affiliation wicri:level="2"><nlm:affiliation>Catedràtica Neurologia U.A.B., Unitat Patologia Neuromuscular, Servei Neurologia, Hospital Santa Creu i Sant Pau, C/ Pare Claret 167, Barcelona 08025, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Catedràtica Neurologia U.A.B., Unitat Patologia Neuromuscular, Servei Neurologia, Hospital Santa Creu i Sant Pau, C/ Pare Claret 167, Barcelona 08025</wicri:regionArea><placeName><region nuts="2" type="communauté">Catalogne</region></placeName></affiliation></author><author><name sortKey="Mantegazza, Renato" sort="Mantegazza, Renato" uniqKey="Mantegazza R" first="Renato" last="Mantegazza">Renato Mantegazza</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Via Celoria 11, 20133 Milano, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Via Celoria 11, 20133 Milano</wicri:regionArea><wicri:noRegion>20133 Milano</wicri:noRegion></affiliation></author><author><name sortKey="Murai, Hiroyuki" sort="Murai, Hiroyuki" uniqKey="Murai H" first="Hiroyuki" last="Murai">Hiroyuki Murai</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, School of Medicine, International University of Health and Welfare, Narita, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, School of Medicine, International University of Health and Welfare, Narita</wicri:regionArea><wicri:noRegion>Narita</wicri:noRegion></affiliation></author><author><name sortKey="Utsugisawa, Kimiaki" sort="Utsugisawa, Kimiaki" uniqKey="Utsugisawa K" first="Kimiaki" last="Utsugisawa">Kimiaki Utsugisawa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Hanamaki General Hospital, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Hanamaki General Hospital</wicri:regionArea><wicri:noRegion>Hanamaki General Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Vissing, John" sort="Vissing, John" uniqKey="Vissing J" first="John" last="Vissing">John Vissing</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, 2082 Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Neurology, 2082 Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen</wicri:regionArea><wicri:noRegion>DK-2100 Copenhagen</wicri:noRegion></affiliation></author><author><name sortKey="Wiendl, Heinz" sort="Wiendl, Heinz" uniqKey="Wiendl H" first="Heinz" last="Wiendl">Heinz Wiendl</name><affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Institute of Translational Neurology, University of Münster, Münster</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Münster</region><settlement type="city">Münster</settlement></placeName></affiliation></author><author><name sortKey="Nowak, Richard J" sort="Nowak, Richard J" uniqKey="Nowak R" first="Richard J" last="Nowak">Richard J. Nowak</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address: richard.nowak@yale.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Yale University School of Medicine, New Haven, CT 06520</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32247193</idno><idno type="pmid">32247193</idno><idno type="doi">10.1016/j.jns.2020.116803</idno><idno type="pmc">PMC7105910</idno><idno type="wicri:Area/Main/Corpus">000839</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000839</idno><idno type="wicri:Area/Main/Curation">000839</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000839</idno><idno type="wicri:Area/Main/Exploration">000839</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.</title><author><name sortKey="Jacob, Saiju" sort="Jacob, Saiju" uniqKey="Jacob S" first="Saiju" last="Jacob">Saiju Jacob</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Institute of Immunology and Immunotherapy, University Hospitals, Birmingham B15 2TH, United Kingdom. Electronic address: saiju.jacob@uhb.nhs.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurology, Institute of Immunology and Immunotherapy, University Hospitals, Birmingham B15 2TH</wicri:regionArea><wicri:noRegion>Birmingham B15 2TH</wicri:noRegion></affiliation></author><author><name sortKey="Muppidi, Srikanth" sort="Muppidi, Srikanth" uniqKey="Muppidi S" first="Srikanth" last="Muppidi">Srikanth Muppidi</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Stanford Neuroscience Health Center, Palo Alto, CA 94304, USA. Electronic address: muppidis@stanford.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Stanford Neuroscience Health Center, Palo Alto, CA 94304</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Guidon, Amanda" sort="Guidon, Amanda" uniqKey="Guidon A" first="Amanda" last="Guidon">Amanda Guidon</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Massachusetts General Hospital, Boston, MA 02114</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Guptill, Jeffrey" sort="Guptill, Jeffrey" uniqKey="Guptill J" first="Jeffrey" last="Guptill">Jeffrey Guptill</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Duke University Medical Center, Durham, NC 27710</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Hehir, Michael" sort="Hehir, Michael" uniqKey="Hehir M" first="Michael" last="Hehir">Michael Hehir</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, University of Vermont Medical Center, Burlington, VT 05401, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Vermont Medical Center, Burlington, VT 05401</wicri:regionArea><placeName><region type="state">Vermont</region></placeName></affiliation></author><author><name sortKey="Howard, James F" sort="Howard, James F" uniqKey="Howard J" first="James F" last="Howard">James F. Howard</name><affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7025, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7025</wicri:regionArea><placeName><region type="state">Caroline du Nord</region><settlement type="city">Chapel Hill (Caroline du Nord)</settlement></placeName><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName></affiliation></author><author><name sortKey="Illa, Isabel" sort="Illa, Isabel" uniqKey="Illa I" first="Isabel" last="Illa">Isabel Illa</name><affiliation wicri:level="2"><nlm:affiliation>Catedràtica Neurologia U.A.B., Unitat Patologia Neuromuscular, Servei Neurologia, Hospital Santa Creu i Sant Pau, C/ Pare Claret 167, Barcelona 08025, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Catedràtica Neurologia U.A.B., Unitat Patologia Neuromuscular, Servei Neurologia, Hospital Santa Creu i Sant Pau, C/ Pare Claret 167, Barcelona 08025</wicri:regionArea><placeName><region nuts="2" type="communauté">Catalogne</region></placeName></affiliation></author><author><name sortKey="Mantegazza, Renato" sort="Mantegazza, Renato" uniqKey="Mantegazza R" first="Renato" last="Mantegazza">Renato Mantegazza</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Via Celoria 11, 20133 Milano, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Via Celoria 11, 20133 Milano</wicri:regionArea><wicri:noRegion>20133 Milano</wicri:noRegion></affiliation></author><author><name sortKey="Murai, Hiroyuki" sort="Murai, Hiroyuki" uniqKey="Murai H" first="Hiroyuki" last="Murai">Hiroyuki Murai</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, School of Medicine, International University of Health and Welfare, Narita, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, School of Medicine, International University of Health and Welfare, Narita</wicri:regionArea><wicri:noRegion>Narita</wicri:noRegion></affiliation></author><author><name sortKey="Utsugisawa, Kimiaki" sort="Utsugisawa, Kimiaki" uniqKey="Utsugisawa K" first="Kimiaki" last="Utsugisawa">Kimiaki Utsugisawa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Hanamaki General Hospital, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Hanamaki General Hospital</wicri:regionArea><wicri:noRegion>Hanamaki General Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Vissing, John" sort="Vissing, John" uniqKey="Vissing J" first="John" last="Vissing">John Vissing</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, 2082 Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Neurology, 2082 Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen</wicri:regionArea><wicri:noRegion>DK-2100 Copenhagen</wicri:noRegion></affiliation></author><author><name sortKey="Wiendl, Heinz" sort="Wiendl, Heinz" uniqKey="Wiendl H" first="Heinz" last="Wiendl">Heinz Wiendl</name><affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Institute of Translational Neurology, University of Münster, Münster</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Münster</region><settlement type="city">Münster</settlement></placeName></affiliation></author><author><name sortKey="Nowak, Richard J" sort="Nowak, Richard J" uniqKey="Nowak R" first="Richard J" last="Nowak">Richard J. Nowak</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address: richard.nowak@yale.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Yale University School of Medicine, New Haven, CT 06520</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author></analytic><series><title level="j">Journal of the neurological sciences</title><idno type="eISSN">1878-5883</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Clinical Trials as Topic (MeSH)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Disease Management (MeSH)</term><term>Disease Susceptibility (MeSH)</term><term>Humans (MeSH)</term><term>Immunoglobulins, Intravenous (therapeutic use)</term><term>Immunologic Factors (therapeutic use)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Immunotherapy (MeSH)</term><term>Lambert-Eaton Myasthenic Syndrome (complications)</term><term>Lambert-Eaton Myasthenic Syndrome (drug therapy)</term><term>Lambert-Eaton Myasthenic Syndrome (therapy)</term><term>Myasthenia Gravis (complications)</term><term>Myasthenia Gravis (drug therapy)</term><term>Myasthenia Gravis (therapy)</term><term>Pandemics (MeSH)</term><term>Plasma Exchange (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>SARS-CoV-2 (MeSH)</term><term>Vaccines (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Betacoronavirus (MeSH)</term><term>Essais cliniques comme sujet (MeSH)</term><term>Facteurs immunologiques (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Immunoglobulines par voie veineuse (usage thérapeutique)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Immunothérapie (MeSH)</term><term>Infections à coronavirus (complications)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (épidémiologie)</term><term>Myasthénie (complications)</term><term>Myasthénie (thérapie)</term><term>Myasthénie (traitement médicamenteux)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (complications)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (épidémiologie)</term><term>Prise en charge de la maladie (MeSH)</term><term>Prédisposition aux maladies (MeSH)</term><term>Syndrome myasthénique de Lambert-Eaton (complications)</term><term>Syndrome myasthénique de Lambert-Eaton (thérapie)</term><term>Syndrome myasthénique de Lambert-Eaton (traitement médicamenteux)</term><term>Vaccins (MeSH)</term><term>Échange plasmatique (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Immunoglobulins, Intravenous</term><term>Immunologic Factors</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Lambert-Eaton Myasthenic Syndrome</term><term>Myasthenia Gravis</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Lambert-Eaton Myasthenic Syndrome</term><term>Myasthenia Gravis</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Lambert-Eaton Myasthenic Syndrome</term><term>Myasthenia Gravis</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Myasthénie</term><term>Syndrome myasthénique de Lambert-Eaton</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Myasthénie</term><term>Pneumopathie virale</term><term>Syndrome myasthénique de Lambert-Eaton</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Facteurs immunologiques</term><term>Immunoglobulines par voie veineuse</term><term>Immunosuppresseurs</term><term>Infections à coronavirus</term><term>Myasthénie</term><term>Pneumopathie virale</term><term>Syndrome myasthénique de Lambert-Eaton</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>COVID-19</term><term>Clinical Trials as Topic</term><term>Disease Management</term><term>Disease Susceptibility</term><term>Humans</term><term>Immunotherapy</term><term>Pandemics</term><term>Plasma Exchange</term><term>SARS-CoV-2</term><term>Vaccines</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term><term>Essais cliniques comme sujet</term><term>Humains</term><term>Immunothérapie</term><term>Pandémies</term><term>Prise en charge de la maladie</term><term>Prédisposition aux maladies</term><term>Vaccins</term><term>Échange plasmatique</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32247193</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5883</ISSN><JournalIssue CitedMedium="Internet"><Volume>412</Volume><PubDate><Year>2020</Year><Month>05</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of the neurological sciences</Title><ISOAbbreviation>J Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.</ArticleTitle><Pagination><MedlinePgn>116803</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0022-510X(20)30139-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jns.2020.116803</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><CollectiveName>International MG/COVID-19 Working Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Jacob</LastName><ForeName>Saiju</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institute of Immunology and Immunotherapy, University Hospitals, Birmingham B15 2TH, United Kingdom. Electronic address: saiju.jacob@uhb.nhs.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muppidi</LastName><ForeName>Srikanth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Stanford Neuroscience Health Center, Palo Alto, CA 94304, USA. Electronic address: muppidis@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guidon</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guptill</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hehir</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Vermont Medical Center, Burlington, VT 05401, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>James F</ForeName><Initials>JF</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Illa</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Catedràtica Neurologia U.A.B., Unitat Patologia Neuromuscular, Servei Neurologia, Hospital Santa Creu i Sant Pau, C/ Pare Claret 167, Barcelona 08025, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mantegazza</LastName><ForeName>Renato</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Via Celoria 11, 20133 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murai</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, International University of Health and Welfare, Narita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utsugisawa</LastName><ForeName>Kimiaki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hanamaki General Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vissing</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, 2082 Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiendl</LastName><ForeName>Heinz</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nowak</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address: richard.nowak@yale.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neurol Sci</MedlineTA><NlmUniqueID>0375403</NlmUniqueID><ISSNLinking>0022-510X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol Sci. 2020 Jul 15;414:116888</RefSource><PMID Version="1">32413767</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1124-1125</RefSource><PMID Version="1">32651248</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015624" MajorTopicYN="N">Lambert-Eaton Myasthenic Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009157" MajorTopicYN="N">Myasthenia Gravis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010951" MajorTopicYN="N">Plasma Exchange</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="N">Vaccines</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32247193</ArticleId><ArticleId IdType="pii">S0022-510X(20)30139-8</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2020.116803</ArticleId><ArticleId IdType="pmc">PMC7105910</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Danemark</li><li>Espagne</li><li>Italie</li><li>Japon</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Californie</li><li>Caroline du Nord</li><li>Catalogne</li><li>Connecticut</li><li>District de Münster</li><li>Massachusetts</li><li>Rhénanie-du-Nord-Westphalie</li><li>Vermont</li></region><settlement><li>Chapel Hill (Caroline du Nord)</li><li>Münster</li></settlement><orgName><li>Université de Caroline du Nord à Chapel Hill</li></orgName></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Jacob, Saiju" sort="Jacob, Saiju" uniqKey="Jacob S" first="Saiju" last="Jacob">Saiju Jacob</name></noRegion></country><country name="États-Unis"><region name="Californie"><name sortKey="Muppidi, Srikanth" sort="Muppidi, Srikanth" uniqKey="Muppidi S" first="Srikanth" last="Muppidi">Srikanth Muppidi</name></region><name sortKey="Guidon, Amanda" sort="Guidon, Amanda" uniqKey="Guidon A" first="Amanda" last="Guidon">Amanda Guidon</name><name sortKey="Guptill, Jeffrey" sort="Guptill, Jeffrey" uniqKey="Guptill J" first="Jeffrey" last="Guptill">Jeffrey Guptill</name><name sortKey="Hehir, Michael" sort="Hehir, Michael" uniqKey="Hehir M" first="Michael" last="Hehir">Michael Hehir</name><name sortKey="Howard, James F" sort="Howard, James F" uniqKey="Howard J" first="James F" last="Howard">James F. Howard</name><name sortKey="Nowak, Richard J" sort="Nowak, Richard J" uniqKey="Nowak R" first="Richard J" last="Nowak">Richard J. Nowak</name></country><country name="Espagne"><region name="Catalogne"><name sortKey="Illa, Isabel" sort="Illa, Isabel" uniqKey="Illa I" first="Isabel" last="Illa">Isabel Illa</name></region></country><country name="Italie"><noRegion><name sortKey="Mantegazza, Renato" sort="Mantegazza, Renato" uniqKey="Mantegazza R" first="Renato" last="Mantegazza">Renato Mantegazza</name></noRegion></country><country name="Japon"><noRegion><name sortKey="Murai, Hiroyuki" sort="Murai, Hiroyuki" uniqKey="Murai H" first="Hiroyuki" last="Murai">Hiroyuki Murai</name></noRegion><name sortKey="Utsugisawa, Kimiaki" sort="Utsugisawa, Kimiaki" uniqKey="Utsugisawa K" first="Kimiaki" last="Utsugisawa">Kimiaki Utsugisawa</name></country><country name="Danemark"><noRegion><name sortKey="Vissing, John" sort="Vissing, John" uniqKey="Vissing J" first="John" last="Vissing">John Vissing</name></noRegion></country><country name="Allemagne"><region name="Rhénanie-du-Nord-Westphalie"><name sortKey="Wiendl, Heinz" sort="Wiendl, Heinz" uniqKey="Wiendl H" first="Heinz" last="Wiendl">Heinz Wiendl</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000548 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000548 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidStanfordV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32247193
|texte= Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32247193" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidStanfordV1
| This area was generated with Dilib version V0.6.38. |  |